Novo Nordisk and the future of obesity drugs; Exit Q&A with AstraZeneca’s Mene Pangalos; Illumina’s bad week; Layoffs sweep biotech; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

With phar­ma earn­ings most­ly over, news may re­al­ly start to slow down next week. But if you’re stick­ing around, be sure to tune in for our in-depth fea­tures and orig­i­nal re­port­ing. Have a great week­end.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.